Electronic Study for Anastrozole Pharmacovigilance Evaluation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1850 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-01-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Early Breast Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Anastrazole safety early breast cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.

Exclusion Criteria

* Metastatic breast cancer patients, previous hormonal therapy, other malignancies.

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nejdet Uskent

Role: PRINCIPAL_INVESTIGATOR

Kadir Has University Medical School

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ARI-IPEP-0104

Identifier Type: -

Identifier Source: org_study_id